Astria Therapeutics Q2 2024 Adj EPS $(0.43) Misses $(0.39) Estimate
Portfolio Pulse from Benzinga Newsdesk
Astria Therapeutics (NASDAQ:ATXS) reported a Q2 2024 adjusted EPS of $(0.43), missing the analyst consensus estimate of $(0.39) by 10.26%.
August 12, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Astria Therapeutics reported a Q2 2024 adjusted EPS of $(0.43), missing the analyst consensus estimate of $(0.39) by 10.26%.
The earnings miss is likely to negatively impact the stock price in the short term as it indicates the company is underperforming relative to analyst expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100